Vertex v. Sun Pharma & Lupin: Kalydeco ANDA Patent Battle Settles After 1,257 Days
Vertex Pharmaceuticals filed suit in Delaware against Sun Pharma, Lupin, and Aurobindo over ANDA filings targeting its Kalydeco ivacaftor 150 mg tablets, asserting US10646481 and US11564916. The parties reached a settlement and license agreement, with Sun agreeing not to market a generic product in the US except as the agreement permits — a result consistent with a controlled market-entry arrangement.
ANDA challenge to Kalydeco resolved via negotiated licence, not adjudication
On July 24, 2020, Vertex Pharmaceuticals filed suit in the District of Delaware against Sun Pharmaceutical Industries, Lupin Limited, Lupin Pharmaceuticals, Aurobindo Pharma USA, and Aurobindo Pharma Limited, asserting infringement of US10646481B2 — a patent covering ivacaftor 150 mg tablets marketed as Kalydeco, a cystic fibrosis CFTR modulator. The action was triggered by Sun’s ANDA No. 214027 containing a Paragraph IV certification, a statutory challenge asserting either invalidity or non-infringement of the listed patent.
The litigation expanded on June 16, 2023, when Vertex filed a second action against Sun following an ANDA amendment directed at US11564916, a later patent in the Kalydeco portfolio. That second action was consolidated with the first on July 10, 2023. On January 2, 2024, the parties filed a stipulated dismissal under Rule 41(a)(2) — all claims, counterclaims, and defences dismissed without prejudice and without costs — accompanied by a settlement and licence agreement whose commercial terms remain confidential.
At 1,257 days, the case ran longer than many ANDA disputes that resolve pre-trial, suggesting substantive patent prosecution or licensing negotiations. The dismissal is explicitly ‘without prejudice’ and ‘not an adjudication on the merits,’ meaning no public validity or infringement ruling was issued. The court retains jurisdiction to enforce the settlement, which is consistent with a negotiated launch-date arrangement — a common feature of Hatch-Waxman resolutions — though the specific entry date is not disclosed in the public record.
Filing to settlement in 1257 days
1,257 days in litigation — roughly 3.4 years, above the median ANDA case duration in Delaware
Settled with licence: what the dismissal terms mean for each party
Rule 41(a)(2) dismissal without prejudice — no merits ruling issued
A Rule 41(a)(2) stipulated dismissal without prejudice terminates the court action but does not adjudicate validity or infringement. The court’s explicit statement that the order ‘shall not act as an adjudication on the merits’ means neither patent is weakened by this outcome. Vertex retains full enforceability of US10646481B2 and US11564916, and the settlement agreement — not the court order — now governs the commercial relationship between the parties.
No merits adjudicationVertex preserves patent enforceability and controls generic entry timing
Settlement with a licence is widely regarded as a favourable outcome for branded pharmaceutical plaintiffs in Hatch-Waxman cases. Vertex avoids any validity risk that trial would have created, retains both asserted patents in full force, and likely secured a defined — and delayed — market entry date for Sun’s generic. The retention of court jurisdiction to enforce the agreement adds a further layer of protection if Sun deviates from agreed terms.
Patents intact, entry date controlledSun gains a negotiated licence — but forfeits the right to launch at will
Sun Pharmaceutical cannot market its ivacaftor generic in the United States except as the settlement and licence agreement expressly permits. This is consistent with a negotiated authorised-generic or delayed-entry licence — commercially valuable for Sun, but representing a constraint on unilateral launch. The public record does not reveal the permitted launch date or royalty terms. The dismissal without prejudice preserves theoretical future claims, but the licence agreement effectively substitutes for litigation going forward.
Licence granted, launch restrictedKalydeco generic entry remains gated — competitive landscape unchanged for now
With no invalidity ruling and a confidential licence controlling Sun’s entry, the Kalydeco market remains substantially protected for Vertex in the near term. Other generic filers — including Lupin and Aurobindo, whose status in the public docket is not fully resolved — may face similar enforceability of the remaining patents. Sector-wide, the outcome reinforces the strategic value of layering multiple patents (here, the ‘481 and ‘916) to extend Hatch-Waxman litigation leverage and negotiate stronger licence terms.
Market access remains protectedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vertex Pharmaceuticals, Inc. | Company | Cystic fibrosis drug innovator — holder of US10646481B2 and US11564916 (Kalydeco ivacaftor)Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic pharmaceutical manufacturers seeking FDA approval to market ivacaftor 150 mg tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alison Hanstead | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | C. Sebastian Zonte | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dimitrios T. Drivas | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joel L. Broussard | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Laura Logsdon | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mila Owen | Attorney | Counsel for Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Vertex Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Dan H. Hoang | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Jovial Wong | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine L. Kyman | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s explicit carve-out — ‘This Stipulation and Order shall not act as an adjudication on the merits’ — is legally significant. It means US10646481B2 and US11564916 emerge from this litigation with no judicial finding on validity or infringement, preserving their full enforceability against third parties. Sun’s agreement to market restrictions except as the licence allows confirms a controlled commercial resolution. The retention of district court jurisdiction is atypical of pure contract settlements and signals the parties sought an enforcement mechanism beyond ordinary contract remedies.
US10646481B2 — Ivacaftor formulation patent covering Kalydeco 150 mg tablets
US10646481B2 (application No. US15/253636) covers ivacaftor 150 mg tablet formulations — the active ingredient in Vertex’s Kalydeco, a CFTR potentiator approved for cystic fibrosis patients with specific CFTR mutations. The patent protects formulation and/or composition aspects of the product, making it a key listed patent in the Orange Book. Its listing triggered the Paragraph IV ANDA certification process that initiated this litigation. US11564916, asserted in the 2023 consolidated action, represents a later-filed patent in the same Kalydeco portfolio, extending the IP barrier for generic entry.
Kalydeco was the first CFTR modulator approved by the FDA and remains commercially significant within Vertex’s cystic fibrosis franchise. The dual-patent Orange Book listing strategy — asserting both the ‘481 and ‘916 patents — is consistent with branded pharmaceutical lifecycle management designed to extend exclusivity and complicate ANDA challenges. With no invalidity ruling from this litigation, both patents retain presumptive validity and are enforceable against subsequent ANDA filers. Competitors and generic manufacturers targeting the ivacaftor market should treat these patents as active enforcement risks until their expiry or a successful IPR challenge.
Should you run an FTO analysis against US10646481B2 and US11564916?
Any company developing, formulating, or seeking regulatory approval for ivacaftor 150 mg tablets — or any CFTR potentiator product with structural or formulation similarity — should conduct a freedom-to-operate analysis against US10646481B2 and US11564916 before advancing to ANDA filing or commercial launch. Both patents survived this litigation without a validity ruling, meaning their claim scope has not been narrowed or invalidated by any court. The settlement’s confidential licence terms provide no public guidance on claim interpretation.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10646481B2 and US11564916 against your product formulation, identify claim elements most likely to read on generic ivacaftor compositions, and flag related continuations or divisionals in the Vertex CFTR portfolio. Eureka’s litigation monitoring tools can also alert you to any new ANDA-related suits Vertex files, giving R&D and regulatory teams early warning before a 30-month stay is triggered.
Run a freedom-to-operate analysis on US10646481B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: CFTR modulators and Hatch-Waxman disputes in Delaware
Browse related Hatch-Waxman paragraph IV patent infringement cases involving CFTR modulators and branded pharmaceutical ANDA challenges litigated in the Delaware District Court.
What this case signals for the cystic fibrosis and ANDA patent IP landscape
Vertex’s dual-patent strategy and negotiated exit provide a clear template for branded pharma defending high-value CFTR assets against Paragraph IV challengers.
Multi-patent stacking in Hatch-Waxman is a proven delay and leverage tool
Vertex’s addition of the ‘916 patent via a second ANDA suit in 2023 — consolidated just months before likely trial — materially increased litigation complexity and leverage. Generic filers challenging single-product portfolios should anticipate late-stage secondary patent assertions and build lifecycle management analysis into ANDA strategy from filing date.
Dismissal without prejudice with court-retained jurisdiction is a distinct settlement structure
The court’s retained jurisdiction to enforce both the stipulation and the licence agreement means Sun remains subject to judicial oversight post-settlement. For generic entrants, this is a meaningful constraint: breach of licence terms can be enforced as a court order, not merely a contract dispute. IP counsel should assess this structure when advising clients on ANDA settlement risk.
Vertex v Sun — key questions answered
Vertex asserted two patents: US10646481B2 (the ‘481 patent) and US11564916 (the ‘916 patent), both covering ivacaftor 150 mg tablet formulations sold under the Kalydeco brand. The ‘481 patent was asserted in the original July 2020 action; the ‘916 patent was added via a second action filed in June 2023 and subsequently consolidated.
The case was resolved by a stipulated dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(2), entered January 2, 2024. The parties entered into a confidential settlement and licence agreement. Sun agreed not to market its ivacaftor generic in the US except as the agreement permits. No costs or attorneys’ fees were awarded, and no merits adjudication was issued.
No. The stipulation expressly states it ‘shall not act as an adjudication on the merits.’ US10646481B2 and US11564916 retain full presumptive validity. No invalidity or non-infringement finding was issued, meaning both patents remain enforceable against other ANDA filers and potential infringers.
Lupin Limited, Lupin Pharmaceuticals, Aurobindo Pharma USA, and Aurobindo Pharma Limited are named defendants in Case No. 1:20-cv-00988. The January 2, 2024 stipulation names only Vertex and Sun as settling parties. The public record does not disclose a separate resolution for Lupin or Aurobindo, suggesting their ANDA status and any litigation exposure may remain unresolved or governed by separate undisclosed agreements.
The settlement reinforces that US10646481B2 and US11564916 are active enforcement assets. Sun’s restricted market entry under a licence — rather than a court ruling of invalidity — means other generic manufacturers cannot rely on this outcome as prior art or estoppel. Any ANDA filer for ivacaftor 150 mg tablets must independently address these patents, either through their own Paragraph IV challenge, a design-around, or a separate licence negotiation with Vertex.
PatSnap Eureka searches patents and litigation data to answer instantly.